Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Kim, Jeong Y ^a   Lee, Eun Y ^a   Lee, Eun B ^a   Lee, Yun J ^b   Yoo, Hyun J ^a   Choi, Jiyong ^a   Song, Yeong W ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; TNFSF11 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; BONE DEVELOPMENT; CELL CULTURE; COCULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; PHYSIOLOGY; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; MALE; OSTEOCLASTS; OSTEOGENESIS; PYRROLES; RANK LIGAND; SYNOVIAL MEMBRANE;

EID: 84865060141     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4018     Document Type: Article

References (35)

1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602. 10.1073/pnas.95.7.3597, 19881, 9520411.
2. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323. 10.1038/16852, 9950424.
3. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004, 50:3831-3843. 10.1002/art.20637, 15593184.
4. Neumann E, Gay S, Muller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005, 52:2960-2967. 10.1002/art.21361, 16200575.
5. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002, 61(Suppl 2):ii84-ii86. 1766721, 12379632.
6. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753. 10.1002/art.10388, 12124857.
7. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40:623-630.
8. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269. 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W, 10693864.
9. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427. 151809, 12438440.
10. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodont Res 2005, 40:287-293. 10.1111/j.1600-0765.2005.00814.x, 15966905.
11. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997, 278:313-321. 10.1001/jama.1997.03550040069040, 9228438.
12. Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI. Am Heart J 1999, 138:S177-S182. 10.1016/S0002-8703(99)70340-6, 10426879.
13. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719. 10.1161/hq1101.098486, 11701455.
14. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003, 99:95-112. 10.1016/S0163-7258(03)00055-X, 12804701.
15. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021. 10.1016/S0140-6736(04)16449-0, 15207950.
16. Mach F. Statins as immunomodulatory agents. Circulation 2004, 109(21 Suppl 1):II15-II17.
17. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003, 2:332-338. 10.1016/S1568-9972(03)00049-1, 14550874.
18. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003, 12:607-611. 10.1191/0961203303lu429oa, 12945719.
19. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011, 38:229-235. 10.3899/jrheum.100582, 21041278.
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581. 10.1002/art.27584, 20872595.
21. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001, 81:153-208.
22. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608. 10.1016/S0140-6736(04)16205-3, 15145635.
23. Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 2005, 16:990-998. 10.1007/s00198-004-1793-0, 15744453.
24. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
25. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?. Arthritis Rheum 2006, 54:393-407. 10.1002/art.21521, 16447216.
26. Kubota A, Hasegawa K, Suguro T, Koshihara Y. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004, 31:426-435.
27. Cohen LH, Pieterman E, van Leeuwen RE, Overhand M, Burm BE, van der Marel GA, van Boom JH. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 2000, 60:1061-1068. 10.1016/S0006-2952(00)00386-5, 11007942.
28. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258. 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P, 10693863.
29. Fujikawa Y, Sabokbar A, Neale S, Athanasou NA. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996, 55:816-822. 10.1136/ard.55.11.816, 1010317, 8976638.
30. Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC, Mountz JD. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 2005, 52:3257-3268. 10.1002/art.21354, 16200600.
31. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
32. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179. 10.1038/36593, 9367155.
33. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194. 10.1074/jbc.272.40.25190, 9312132.
34. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000, 43:2501-2512. 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K, 11083274.
35. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 1996, 39:197-203. 10.1002/art.1780390205, 8849369.